BioSpace News Archive

Global health services company Cigna Corporation (NYSE:CI) announced today that Brian Evanko, executive vice president and chief financial officer, will present at the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022 in Rancho Palos Verdes, CA.

Aerin Medical Inc. announced that the American Medical Association Current Procedural Terminology Editorial Panel accepted the application for a new Category I CPT code to report endoscopic destruction of the posterior nasal nerve using radiofrequency ablation.

Paragonix Technologies, Inc., a leader in Advanced Organ Preservation technology, has announced the launch of its new VantagePoint™ Organ Tracking Technology to pioneer a new era of continuous oversight and real-time visibility for donor organs in transit.

Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”) announced today that the company has entered into a worldwide licensing agreement with Syncromune, Inc. (“Syncromune”), a US-based clinical stage biopharmaceutical company, for the development and commercialization of intratumoral immunotherapies along with Syncromune’s Syncrovax™ technology.

Scopus BioPharma Inc. announced the completion of a series of related recapitalization transactions designed to enhance shareholder value.

ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the further expansion of their leadership team and clinical development capabilities through the appointment of Feriandas Greblikas, M.D. as Vice President of Clinical Development.

China’s research and development industry has recently been flourishing with support from the government’s newer policies and increasing investment

Australian industrial biotechnology leader MicroBioGen (“the Company”) officially opened its state-of-the-art laboratories in Macquarie Park in Northern Sydney this weekend. The labs will produce world-leading micro-organisms that are essential to industries worth over US$2 trillion per year, including biofuels, alternative proteins, space exploration, sustainable human foods and animal feed.

People with spinal muscular atrophy are relying on recently approved condition-specific treatments and are hopeful the treatment pipeline can continue to have a positive impact, according to a recent survey conducted by Health Union, the leader in social health.

Vascular Dynamics, Inc. (VDI) announced that a study assessing its MobiusHD device to treat patients with chronic heart failure has been published in the peer-reviewed journal, Structural Heart.